• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ayala Pharmaceuticals Inc (OP: ADXS )

    0.2625 UNCHANGED
    Streaming Delayed Price Updated: 1:14 PM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.2625
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.2625
    Today's Range 0.2625 - 0.2625
    52wk Range 0.1350 - 1.950
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
    From Ayala Pharmaceuticals
    Via GlobeNewswire

    Performance

    YTD
    -58.33%
    -58.33%
    1 Month
    -12.50%
    -12.50%
    3 Month
    -55.51%
    -55.51%
    6 Month
    -58.33%
    -58.33%
    1 Year
    -72.94%
    -72.94%

    More News

    Read More
    Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
    From Immunome, Inc.
    Via Business Wire
    Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces Closing of Merger with Biosight
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
    Via Benzinga
    Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
    Via News Direct
    Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ
    Via Benzinga
    Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
    From Kahn Swick & Foti, LLC
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.